Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 4/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | TNF | P01375 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30875689 | 0.97 | ALDH1A1 (0.50) | ALDH1A1CYP2C19LMNAHTTL3MBTL1 | |
| SCHEMBL11302461 | 0.97 | ALDH1A1 (0.50) | ALDH1A1CYP2C19LMNAHTTL3MBTL1 | |
| SCHEMBL3311892 | 0.93 | ALDH1A1 (0.52) | ALDH1A1CYP2C19LMNAHTTL3MBTL1 | |
| SCHEMBL14797532 | 0.86 | ALDH1A1 (0.49) | ALDH1A1CYP2C19LMNAHTTL3MBTL1 | |
| SCHEMBL28526142 | 0.85 | ALDH1A1 (0.47) | ALDH1A1LMNAL3MBTL1MAPTKDM4E | |
| SCHEMBL14626974 | 0.82 | L3MBTL1 (0.52) | ALDH1A1CYP2C19LMNAL3MBTL1MAPT | |
| SCHEMBL3726022 | 0.82 | TSHR (0.49) | ALDH1A1LMNAL3MBTL1MAPTKDM4E | |
| SCHEMBL7649624 | 0.82 | SIRT6 (0.47) | ALDH1A1LMNAMAPTKDM4ETDP1 | |
| SCHEMBL28619122 | 0.81 | ALDH1A1 (0.47) | ALDH1A1CYP2C19LMNAHTTL3MBTL1 | |
| SCHEMBL2729882 | 0.81 | ALDH1A1 (0.47) | ALDH1A1CYP2C19LMNAHTTL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230227483-A1 | PYRIMIDINE COMPOUNDS FOR USE AS MAP4K1 INHIBITORS | GLENMARK SPECIALITY S.A. (CH) | 2023-07-20 | — | — | US | disclosed |
| US-20230227483-A1 | PYRIMIDINE COMPOUNDS FOR USE AS MAP4K1 INHIBITORS | GLENMARK SPECIALITY S.A. (CH) | 2023-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230227483-A1 | PYRIMIDINE COMPOUNDS FOR USE AS MAP4K1 INHIBITORS | MAP4K1, MAP3K4, MAP4K2 | ALDH1A1 2196/4885CYP2C19 3621/4885LMNA 2435/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.